{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:07:27Z","timestamp":1787238447947,"version":"build-2736575974"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.phrs.2018.06.026","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T18:03:44Z","timestamp":1530036224000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Changes in left ventricular geometry during antihypertensive treatment"],"prefix":"10.1016","volume":"134","author":[{"given":"Massimo","family":"Salvetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Paini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Bertacchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Stassaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4044-7256","authenticated-orcid":false,"given":"Carlo","family":"Aggiusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Agabiti Rosei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Agabiti-Rosei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4007-9441","authenticated-orcid":false,"given":"Maria Lorenza","family":"Muiesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.06.026_bib0005","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM199005313222203","article-title":"Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study","volume":"322","author":"Levy","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.06.026_bib0010","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1097\/HJH.0b013e32833d95fe","article-title":"Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk","volume":"28","author":"Tsioufis","year":"2010","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/00004872-200207000-00017","article-title":"Role of echocardiography and carotid ultrasonography in stratifying risk in patients with essential hypertension","volume":"20","author":"Cuspidi","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0020","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1067\/mhj.2001.113218","article-title":"Prognostic implications of left ventricular hypertrophy","volume":"141","author":"Vakili","year":"2001","journal-title":"Am. Heart J."},{"issue":"Suppl. 14","key":"10.1016\/j.phrs.2018.06.026_bib0025","first-page":"101","article-title":"Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials","volume":"S95","author":"Devereux","year":"1996","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0030","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/00004872-199510000-00003","article-title":"Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment","volume":"13","author":"Muiesan","year":"1995","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0035","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1161\/01.HYP.0000121223.44837.de","article-title":"Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients","volume":"43","author":"Muiesan","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0040","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1093\/ejechocard\/jen155","article-title":"Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study)","volume":"9","author":"Gerdts","year":"2008","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.phrs.2018.06.026_bib0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/ajh\/5.2.95","article-title":"Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies","volume":"5","author":"Dahl\u00f6f","year":"1992","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0050","first-page":"85","article-title":"Reversibility of left ventricular hypertrophy by differing types of antihypertensive therapy","volume":"6","author":"Cruickshank","year":"1992","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0055","series-title":"Handbook of Hypertension","article-title":"Reversibility of left ventricular hypertrophy and malfunction by antihypertensive treatment","author":"Jennings","year":"1997"},{"key":"10.1016\/j.phrs.2018.06.026_bib0060","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ndt\/13.3.564","article-title":"Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)","volume":"13","author":"Schmieder","year":"1998","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.phrs.2018.06.026_bib0065","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9343(03)00158-X","article-title":"A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension","volume":"115","author":"Klingbeil","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.phrs.2018.06.026_bib0070","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/HYPERTENSIONAHA.109.136655","article-title":"Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies","volume":"54","author":"Fagard","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0075","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1097\/01.hjh.0000166852.18463.5e","article-title":"Cardiac structural and functional changes during long-term antihypertensive treatment with lacidipine and atenolol in the European lacidipine study on atherosclerosis (ELSA)","volume":"23","author":"Agabiti-Rosei","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0080","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/00004872-199511000-00015","article-title":"ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group","volume":"13","author":"Agabiti-Rosei","year":"1995","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00228-005-0931-8","article-title":"Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension","volume":"61","author":"Anan","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0090","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/01.STR.0000236839.69658.c5","article-title":"Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension","volume":"37","author":"Ariff","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2018.06.026_bib0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/080370598437484","article-title":"Effects of amlodipine and lisinopril on left ventricular mass and diastolic function in previously untreated patients with mild to moderate diastolic hypertension","volume":"7","author":"Beltman","year":"1998","journal-title":"Blood Press."},{"key":"10.1016\/j.phrs.2018.06.026_bib0100","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/0002-9149(92)90936-S","article-title":"Comparison of the effects of isradipine and lisinopril on left ventricular structure and function in essential hypertension","volume":"69","author":"Bielen","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0105","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1097\/00004872-200211000-00030","article-title":"Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study","volume":"20","author":"Cuspidi","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0110","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/00004872-199210120-00012","article-title":"Regression of left ventricular hypertrophy in previously untreated essential hypertension: different effects of enalapril and hydrochlorothiazide","volume":"10","author":"Dahlof","year":"1992","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0115","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1097\/01.hjh.0000187253.35245.dc","article-title":"Perindopril\/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study","volume":"23","author":"Dahl\u00f6f","year":"2005","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0120","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1097\/00004872-200209000-00032","article-title":"Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy","volume":"20","author":"Dahlof","year":"2002","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0125","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1161\/hc3601.095927","article-title":"Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluat","volume":"104","author":"Devereux","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0130","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1161\/01.CIR.0000141573.44737.5A","article-title":"Regression of hypertensive left ventricular hypertrophy by Losartan compared with atenolol: the losartan intervention for endpoint reduction in hypertension (LIFE) trial","volume":"110","author":"Devereux","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00005344-199811000-00012","article-title":"Benazepril causes in hypertension a greater reduction in left ventricular mass than does nitrendipine: a randomized study using magnetic resonance imaging","volume":"32","author":"Gaudio","year":"1998","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0140","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/00004872-199816050-00017","article-title":"Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension","volume":"16","author":"Gerritsen","year":"1998","journal-title":"J. Hypertens."},{"issue":"Suppl 5","key":"10.1016\/j.phrs.2018.06.026_bib0145","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1097\/00005344-199006165-00026","article-title":"Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: effects on left ventricular hypertrophy","volume":"16","author":"Gosse","year":"1990","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0150","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1161\/01.CIR.95.8.2007","article-title":"Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The department of veterans affairs cooperative study group on antihypertensive agents","volume":"95","author":"JS","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0155","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1378\/chest.96.1.74","article-title":"Comparison of antihypertensive therapies by noninvasive techniques","volume":"96","author":"Craettinger","year":"1989","journal-title":"Chest"},{"key":"10.1016\/j.phrs.2018.06.026_bib0160","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/01.CIR.91.3.698","article-title":"Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the treatment of mild hypertension study (TOMHS)","volume":"91","author":"Liebson","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0165","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0002-8703(97)70095-4","article-title":"Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension","volume":"134","author":"Lombardo","year":"1997","journal-title":"Am. Heart J."},{"key":"10.1016\/j.phrs.2018.06.026_bib0170","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1097\/00004872-200106000-00023","article-title":"Regression of left ventricular hypertrophy in human hypertension with irbesartan","volume":"19","author":"Malmqvist","year":"2001","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0175","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/08037050152112087","article-title":"Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism","volume":"10","author":"Malmqvist","year":"2001","journal-title":"Blood Press."},{"key":"10.1016\/j.phrs.2018.06.026_bib0180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/S0895-7061(98)00036-3","article-title":"Comparison of spirapril, isradipine, or combination in hypertensive patients with left ventricular hypertrophy: effects on LVH regression and arrhythmogenic propensity","volume":"11","author":"Manolis","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00007890-200107150-00021","article-title":"Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study","volume":"72","author":"Midtvedt","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0190","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1365-2796.1992.tb00965.x","article-title":"Changes in left ventricular dimensions and systolic function in 100 mildly hypertensive men during one year\u2019r treatment with atenolol vs. hydrochlorothiazide and amiloride (Moduretic): a double\u2010blind, randomized study","volume":"231","author":"Otterstad","year":"1992","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.phrs.2018.06.026_bib0195","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0735-1097(97)00311-2","article-title":"Hydrochlorothiazide is superior to isradipine for reduction of left ventricular mass: results of a multicenter trial","volume":"30","author":"Papademetriou","year":"1997","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0200","first-page":"672","article-title":"Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study","volume":"43","author":"Raki\u0107","year":"2002","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.phrs.2018.06.026_bib0205","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-7061(97)00492-5","article-title":"Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy","volume":"11","author":"Roman","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0210","first-page":"147","article-title":"Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment","volume":"12","author":"Rosatti","year":"1995","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2018.06.026_bib0215","first-page":"117","article-title":"Comparative effect of clinidipine and quinapril on left ventricular mass in mild essential hypertension","volume":"29","author":"Sakata","year":"2003","journal-title":"Drugs Exp. Clin. Res."},{"key":"10.1016\/j.phrs.2018.06.026_bib0220","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.23.1.83","article-title":"Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension","volume":"23","author":"Schiffrin","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0225","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199005103221904","article-title":"The effects of antihypertensive therapy on left ventricular mass in elderly patients","volume":"322","author":"Schulman","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2018.06.026_bib0230","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/0002-9149(92)91192-7","article-title":"Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine","volume":"70","author":"Schulte","year":"1992","journal-title":"Am. J. Cardiol."},{"issue":"Suppl 6","key":"10.1016\/j.phrs.2018.06.026_bib0235","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1097\/00005344-199312050-00017","article-title":"Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study","volume":"22","author":"Senior","year":"1993","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0240","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0895-7061(97)00475-5","article-title":"Effect of antihypertensive treatment on cardiac and subcutaneous artery structure: a comparison between calcium channel blocker and thiazide-based regimens","volume":"11","author":"Sihm","year":"1998","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/sj.jhh.1000685","article-title":"Effects of losartan on hypertension and left ventricular mass: a long-term study","volume":"12","author":"Tedesco","year":"1998","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0250","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.jhh.1001305","article-title":"Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients","volume":"16","author":"De Rosa","year":"2002","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0255","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004872-199715030-00013","article-title":"Reduction of left ventricular mass by antihypertensive treatment does not improve exercise performance in essential hypertension","volume":"15","author":"Fagard","year":"1997","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0260","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1253\/circj.70.995","article-title":"Effects of spironolactone during an angiotensin II receptor blocker treatment on the left ventricular mass reduction in hypertensive patients with concentric left ventricular hypertrophy","volume":"70","author":"Taniguchi","year":"2006","journal-title":"Circ. J."},{"key":"10.1016\/j.phrs.2018.06.026_bib0265","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1097\/00004872-200018100-00015","article-title":"Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study","volume":"18","author":"Gosse","year":"2000","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0270","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1161\/HYPERTENSIONAHA.113.01360","article-title":"Long-term antihypertensive treatment fails to improve E\/e\u2032 despite regression of left ventricular mass: an Anglo-Scandinavian cardiac outcomes trial substudy","volume":"63","author":"Barron","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0275","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1161\/01.CIR.98.19.2037","article-title":"Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension","volume":"98","author":"Thurmann","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2018.06.026_bib0280","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0895-7061(04)00815-5","article-title":"Regression of left ventricular mass in hypertensive patients treated with perindopril\/indapamide as a first-line combination: the REASON echocardiography study","volume":"17","author":"De Luca","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0285","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1097\/HJH.0b013e3283480fe9","article-title":"Effects of perindopril-indapamide on left ventricular diastolic function and mass in patients with type 2 diabetes: the ADVANCE echocardiography substudy","volume":"29","author":"Group","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/sj.jhh.1000544","article-title":"Treatment of diastolic dysfunction in hypertensive patients without left ventricular hypertrophy","volume":"12","author":"Molinero","year":"1998","journal-title":"J. Hum. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0295","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/00005344-200311000-00007","article-title":"Comparative effects of irbesartan versus amlodipine on left ventricular mass index in hypertensive patients with left ventricular hypertrophy","volume":"42","author":"Gaudio","year":"2003","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.phrs.2018.06.026_bib0300","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.amjhyper.2004.02.010","article-title":"Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry","volume":"17","author":"Libhaber","year":"2004","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0305","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/01.STR.30.5.1056","article-title":"Changes in arterial structure and function under trandolapril-verapamil combination in hypertension","volume":"30","author":"Topouchian","year":"1999","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2018.06.026_bib0310","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/echo.12548","article-title":"Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy","volume":"31","author":"Motoki","year":"2014","journal-title":"Echocardiography"},{"key":"10.1016\/j.phrs.2018.06.026_bib0315","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.HYP.0000133249.28773.d7","article-title":"Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the cardiovascular irbesartan project","volume":"44","author":"Schneider","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0320","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1023\/A:1007739504829","article-title":"Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension, but calcium antagonist also depresses contractility","volume":"11","author":"Sumimoto","year":"1997","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2018.06.026_bib0325","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/HJH.0b013e32834103d4","article-title":"Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication","volume":"29","author":"Yoshida","year":"2011","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0330","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10641963.2013.764892","article-title":"Comparison of the effect of combination therapy with an angiotensin II receptor blocker and either a low-dose diuretic or calcium channel blocker on cardiac hypertrophy in patients with hypertension","volume":"35","author":"Okura","year":"2013","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0335","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"10.1016\/j.phrs.2018.06.026_bib0340","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.euje.2005.12.014","article-title":"Recommendations for chamber quantification","volume":"7","author":"Lang","year":"2006","journal-title":"Eur. J. Echocardiogr."},{"key":"10.1016\/j.phrs.2018.06.026_bib0345","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3109\/10641969909061028","article-title":"1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization","volume":"21","author":"Chalmers","year":"1999","journal-title":"Clin. Exp. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0350","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1097\/00004872-200311000-00002","article-title":"2003 World Health Organization (WHO)\/International Society of Hypertension (ISH) statement on management of hypertension","volume":"21","author":"Whitworth","year":"2003","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0355","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00059-006-2829-3","article-title":"ESH-ESC guidelines for the management of hypertension","volume":"31","author":"Erdine","year":"2006","journal-title":"Herz"},{"key":"10.1016\/j.phrs.2018.06.026_bib0360","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/eurheartj\/eht151","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"34","author":"Mancia","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2018.06.026_bib0365","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/ajh.2007.85","article-title":"Studies on left ventricular hypertrophy regression in arterial hypertension: a clear message for the clinician?","volume":"21","author":"Cuspidi","year":"2008","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0370","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1097\/HJH.0000000000000280","article-title":"Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricularmass regression in patients with resistant hypertension","volume":"32","author":"Azizi","year":"2014","journal-title":"J. Hypertens."},{"key":"10.1016\/j.phrs.2018.06.026_bib0375","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/HYPERTENSIONAHA.115.06467","article-title":"Effects of $\u03b2$-blockers with and without vasodilating properties on central blood pressure: systematic review and meta-analysis of randomized trials in hypertension","volume":"67","author":"Pucci","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0380","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/HYPERTENSIONAHA.107.107474","article-title":"Gender differences in left ventricular structure and function during antihypertensive treatment: the losartan intervention for endpoint reduction in hypertension study","volume":"51","author":"Gerdts","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.phrs.2018.06.026_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/JAHA.113.000144","article-title":"Lack of reduction of left ventricular mass in treated hypertension: the strong heart study","volume":"2","author":"De Simone","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2018.06.026_bib0390","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3109\/08037051.2013.858482","article-title":"Impact of isolated systolic hypertension on normalization of left ventricular structure during antihypertensive treatment (the LIFE study)","volume":"23","author":"Mancusi","year":"2014","journal-title":"Blood Press."},{"key":"10.1016\/j.phrs.2018.06.026_bib0395","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1161\/HYPERTENSIONAHA.115.06236","article-title":"Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with diabetes mellitus: action to control cardiovascular risk in diabetes blood pressure trial","volume":"66","author":"Soliman","year":"2015","journal-title":"Hypertension"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661818302743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:56:12Z","timestamp":1760910972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661818302743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":79,"alternative-id":["S1043661818302743"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.06.026","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in left ventricular geometry during antihypertensive treatment","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.06.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}